Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1483457 | 1.00 | BCHE (0.42) | BCHEMAPTALDH1A1ROCK2ROCK1 | |
| SCHEMBL1483452 | 1.00 | BCHE (0.42) | BCHEMAPTALDH1A1ROCK2ROCK1 | |
| SCHEMBL10030647 | 0.83 | BCHE (0.59) | BCHEMAPTALDH1A1ROCK2ROCK1 | |
| SCHEMBL10030646 | 0.83 | BCHE (0.59) | BCHEMAPTALDH1A1ROCK2ROCK1 | |
| SCHEMBL12829089 | 0.83 | BCHE (0.39) | BCHEPRSS1TPSG1 | |
| SCHEMBL637594 | 0.82 | MAPT (0.59) | BCHEMAPTALDH1A1ROCK2ROCK1 | |
| SCHEMBL637595 | 0.82 | MAPT (0.59) | BCHEMAPTALDH1A1ROCK2ROCK1 | |
| SCHEMBL1551375 | 0.81 | BCHE (0.40) | BCHEMAPTALDH1A1ROCK2ROCK1 | |
| SCHEMBL1551373 | 0.81 | BCHE (0.40) | BCHEMAPTALDH1A1ROCK2ROCK1 | |
| SCHEMBL637892 | 0.76 | CYP1A2 (0.46) | BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313417-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | Nicox S.A. (FR) | 2011-04-27 | — | — | EP | disclosed |
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2011-03-31 | — | — | US | disclosed |
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2011-03-31 | — | — | US | disclosed |
| WO-2009150007-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, AGT | BCHE 2032/4885MAPT 3856/4885ALDH1A1 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.